Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
 1 a 20 de 33 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016;388:187-97. [Ref.ID 100623]
2. Cita con resumen
Peyvandi F, Scully M, Kremer HJA, Cataland S, Knöbl P, Wu H, Antoni A, Westwood JP, Mansouri TM, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016;374:511-22. [Ref.ID 100129]
3.Enlace a cita originalTiene citas relacionadas
Kazmi RS, Lwaleed BA. New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol 2011;72:593-603. [Ref.ID 91566]
4.Enlace a cita originalTiene citas relacionadas
Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011;72:581-92. [Ref.ID 91565]
5.Enlace a cita originalTiene citas relacionadas
Toschi V, Lettino M. Inhibitors of propagation of coagulation: factors V and X. Eur J Clin Pharmacol 2011;72:563-80. [Ref.ID 91564]
6.Enlace a cita originalTiene citas relacionadas
Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Eur J Clin Pharmacol 2011;72:553-62. [Ref.ID 91563]
7. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
8. Cita con resumen
Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. N Engl J Med 2008;358:843-9. [Ref.ID 82210]
9.Enlace a cita original Cita con resumen
Coombes R. Bad blood. BMJ 2007;334:879-80. [Ref.ID 79955]
10. Cita con resumen
Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, Ritchie B, Siegel J, Simmonds P, Stanley S, Tapper ML, von Depka M. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet 2006;367:252-61. [Ref.ID 76000]
12. Cita con resumen
Anónimo. Bayer pharma pins turnaround hopes on two products. Scrip 2005;3038:10. [Ref.ID 73180]
13.
Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-94. [Ref.ID 71112]
14. Cita con resumen
Anónimo. Baxter cuts price of Advate to boost sales. Scrip 2004;2952:9. [Ref.ID 70157]
15.
Porte R J, Leebeek FWG. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002;62:2193-211. [Ref.ID 63853]
16.
Petrini P. Treatment strategies in children with hemophilia. Pediatr Drugs 2002;4:427-37. [Ref.ID 62721]
17.Tiene citas relacionadas
Mannucci PM, Tudenham EGD. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001;344:1773-9. [Ref.ID 56867]
18.Tiene citas relacionadas
Miller DG, Stamatoyannopoulos G. Gene therapy for hemophilia. N Engl J Med 2001;344:1782-4. [Ref.ID 56857]
19.Tiene citas relacionadas Cita con resumen
Roth D A, Tawa NE, O'Brien JM, Treco D A, Selden RF, for the Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001;344:1735-42. [Ref.ID 56853]
20.
Geffken DF, Cushman M, Burke GL, Polak J F, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 2001;153:242-50. [Ref.ID 55101]
Seleccionar todas
 
 1 a 20 de 33 siguiente >>